Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
06/2010
06/15/2010US7737161 such as 5-amino-N-(5-chloropyridin-2-yl)-3-{[(trans-4-pyrrolidin-1-ylcyclohexyl)carbonyl]amino}furo[3,2-b]pyridine-2-carboxamide, used as activated blood coagulation factor X inhibitors
06/15/2010CA2493391C Novel thiophene glycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
06/15/2010CA2442256C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
06/15/2010CA2393650C Novel 1,8-naphthyridin-2(1h)-one derivatives
06/15/2010CA2341700C Compositions and methods for treatment of mitochondrial diseases
06/10/2010WO2010065571A1 Treatment for glomerulonephritis with 2 - [ 4- ( -7-ethyl-5h-pyrrolo [ 2,3-b ] -pyrazin- 6 -yl) propan-2-ol
06/10/2010WO2010064714A1 Nutrient composition
06/10/2010WO2010064707A1 2h-chromene compound and derivative thereof
06/10/2010WO2010064597A1 Piperidine derivative
06/10/2010WO2010063471A1 Inhibitors of hif-1 protein accumulation
06/10/2010US20100144876 Modulator
06/10/2010US20100144809 Novel benzamidine derivatives useful as potassium channel modulators
06/10/2010US20100144801 Muscarinic receptor antagonists
06/10/2010US20100144798 Modulators of ATP-Binding Cassette Transporters
06/10/2010US20100144699 Combination Medicaments for Treating Bacterial Infections
06/10/2010US20100144684 Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
06/10/2010US20100144639 Use of inhibitors of the egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph) / prostatic hypertrophy
06/10/2010US20100144631 Concentrated Protein Preparations of Bone Morphogenetic Proteins and Methods of Use Thereof
06/10/2010US20100144624 Process for the preparation of compositions of at1 receptor antagonist and angiotensin-(1-7)
06/10/2010US20100143470 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
06/10/2010US20100143287 Trifluoromethylphenyl modulators of calcium-sensing receptor
06/10/2010CA2745356A1 2h-chromene compound and derivative thereof
06/10/2010CA2745199A1 Treatment for glomerulonephritis with 2 - [ 4- ( -7-ethyl-5h-pyrrolo [ 2,3-b ] -pyrazin- 6 -yl) propan-2-ol
06/10/2010CA2744391A1 Inhibitors of hif-1 protein accumulation
06/09/2010EP2194045A1 Substituted pyrazole derivative
06/09/2010EP2194044A1 Quinolone derivative
06/09/2010EP2193788A1 Pharmaceutical compositions comprising colloidal silicon dioxide
06/09/2010EP1497273B1 Hydroxamic acid derivatives
06/09/2010EP1385864B1 Anti-VEGF-2 antibodies
06/09/2010EP1335907B1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
06/09/2010EP1270004B1 Use of gamma-tocotrienol as diuretic
06/09/2010CN1986568B INF-alpha expression relevant protein and its coding gene
06/09/2010CN1905876B Use of dipeptidyl peptidase IV inhibitors
06/09/2010CN1826099B Pharmaceutical composition as solid dosage form and method for manufacturing thereof
06/09/2010CN1739679B Medicine for treating nephrolithiasis and its preparation method
06/09/2010CN1733197B Medicine for curing chronic prostatitis and process for preparing the same
06/09/2010CN1662511B Pharmaceutical salts of reboxetine
06/09/2010CN1646115B Use of SARMS in preparing medicine for treating benign prostate hyperplasia
06/09/2010CN101730469A Pesticidal composition comprising a strigolactone derivative and an fungicide compound
06/09/2010CN101724539A Formula of health-care wine and preparation method thereof
06/09/2010CN101724070A humanized anti-ngf antibodies
06/09/2010CN101723948A C-6 modified indazolylpyrrolotriazines
06/09/2010CN101721656A Medicine composition for curing lithiasis and preparation method thereof
06/09/2010CN101721627A Traditional Chinese medicine for treating acute glomerulonephritis
06/09/2010CN101721626A Traditional Chinese medicine for treating prostatitis
06/09/2010CN101721625A Quality control method of shenyankangfu tablet
06/09/2010CN101721577A Method for preparing film coating tablet for treating chronic renal failure
06/09/2010CN101721528A Medicine composition for treating chronic prostatitis
06/09/2010CN101721521A Chinese medicinal herb pills for dissolving stones and expelling stones
06/09/2010CN101721468A Method for preparing salvianolic acids
06/09/2010CN101721467A Method for preparing total salvianolic acid
06/09/2010CN101721462A Method for harvesting and primarily processing sianchau
06/09/2010CN101721429A Application of amniotic epithelial cells and cell preparations thereof
06/09/2010CN101721370A Goserelin release microsphere preparation, preparation method and detecting method thereof
06/09/2010CN101721363A Cefixime oral administration mixed suspension and preparation method thereof
06/09/2010CN101195011B Chinese medicine for treating prostatitis and hyperplasia
06/09/2010CN101181466B Chinese traditional medicine for curing nephrosis
06/09/2010CN101181344B Chinese medicine medicament for curing renal calculs
06/09/2010CN101095439B Instant tea and method for preparing the same
06/08/2010US7732488 Marine oil derived ethyl ester of eicosapentaenoic acid and docosahexaenoic acid, with specified reduced levels of brominated flame retardants; not a health supplement; treat hypertriglyceridaemia
06/08/2010US7732456 such as 4-benzyloxy-1-{4-[2-(dimethylamino)ethoxy]phenyl}-1H-pyridin-2-one, that as antagonists to melanin concentrating hormone receptors, used for treating cardiovascular, nervous system, metabolic, reproductive system, respiratory system and gatrointestinal disorders
06/08/2010US7732146 Method for screening an agent that modulates activity of macrophage migration inhibitory factor
06/08/2010US7731955 Using lactoperoxidase composition as a therapeutic treatment for rheumatoid arthritis, sepsis, myleoma and influenza infection
06/08/2010CA2479642C 4-anilino quinazoline derivatives as antiproliferative agents
06/08/2010CA2439241C Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
06/03/2010WO2010061903A1 Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
06/03/2010WO2010060387A1 The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof
06/03/2010WO2009109654A8 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
06/03/2010US20100137427 Softgel of NLKJ for treating prostate diseases
06/03/2010US20100137409 Compositions and Methods for the Treatment of Diseases Associated with Aberrant Cilia Assembly and Regulation
06/03/2010US20100137399 Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
06/03/2010US20100137392 overactive bladder; oxybutynin and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin; reduced dry mouth side effect
06/03/2010US20100137364 6-Aminoisoquinoline Compounds
06/03/2010US20100137363 Substituted Indoles And Methods Of Their Use
06/03/2010US20100137361 Tetrahydro-Quinolinylurea Derivatives
06/03/2010US20100137358 Solifenacin compositions
06/03/2010US20100137340 Fused pyrimidinone compounds as mglur ligands
06/03/2010US20100137332 Piperazine modulators of nk-1 receptors
06/03/2010US20100137324 Rho-kinase inhibitors
06/03/2010US20100137301 Substituted Indolealkanoic Acids
06/03/2010US20100137251 Functional Role for Cannabinoids in Autonomic Stability During Sleep
06/03/2010US20100137198 Pharmaceutical composition for topical application
06/03/2010US20100136142 Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
06/03/2010US20100136122 Oral Preparation Comprising Pioglitazone
06/03/2010US20100136028 Antagonists of pcsk9
06/03/2010US20100136017 Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
06/03/2010US20100135988 Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or alpha1 type IV collagen
06/03/2010US20100135952 Methods for the treatment of renal failure
06/03/2010CA2744828A1 Five crystal forms, methods of preparation, pharmaceutical compositions and applications of 3-(3'-carboxy-4'-hydroxy-anilino-carbo-)-6-nitro-7-hydroxy-8-methyl-coumarin)>>
06/02/2010EP2191839A2 Immunogenic LHRH compositions and methods relating thereto
06/02/2010EP2190465A2 Use of a peptide as a therapeutic agent
06/02/2010EP2190433A2 Therapy for complications of diabetes
06/02/2010EP1483228B1 Nk1 antagonists
06/02/2010DE112008001179T5 Mittel für die Behandlung und zur Vorsorge von gutartiger Prostatahyperplasie, Prostatitis, Impotenz, Unfruchtbarkeit und Prostatakarzinom und das Verfahren seiner Anwendung Agents for the treatment and prevention of benign prostatic hyperplasia, prostatitis, impotence, infertility, and prostate cancer, and the method of its application
06/02/2010CN1994433B Kidney-tonifying health product and preparation method thereof
06/02/2010CN1972698B Beta-hydroxy short to medium chain fatty acid polymer
06/02/2010CN1659180B Novel recombinant anticoagulant proteins
06/02/2010CN101717419A 5alpha-reductase urtica open-loop lignan glycoside D inhibitor, preparation method thereof and use thereof
06/02/2010CN101717416A Derivative of alpha-amino phosphonic acid containing saccharide groups, preparation method and medical application thereof
06/02/2010CN101717407A Highly substituted alpha-amino phosphonate derivative as well as preparation method and medical application thereof
1 ... 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 ... 562